Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|124|2|297-305

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.2, 2018-01, pp. : 297-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3051-3058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival and Prognostic Factors in Patients with Brain Metastases from Malignant Melanoma

By  

Oncology Research and Treatment, Vol. 27, Iss. 2, 2004-05 ,pp. : 145-149

Karger

Access to resources Recommend Favorite

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

By  

Oncology, Vol. 93, Iss. 3, 2017-06 ,pp. : 164-176

Karger

Access to resources Recommend Favorite

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

By  

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 530-536

John Wiley & Sons Inc

Access to resources Recommend Favorite